Published in Cancer Prev Res (Phila) on April 19, 2011
Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol (2013) 1.28
Reproductive factors and risk of oesophageal and gastric cancer in the Million Women Study cohort. Br J Cancer (2011) 0.88
Association between circulating levels of sex steroid hormones and Barrett's esophagus in men: a case-control analysis. Clin Gastroenterol Hepatol (2014) 0.87
Estrogen, male dominance and esophageal adenocarcinoma: is there a link? World J Gastroenterol (2012) 0.84
Reproductive factors and risk of esophageal squamous cell carcinoma in northern Iran: a case-control study in a high-risk area and literature review. Eur J Cancer Prev (2013) 0.83
Genetic variants in sex hormone metabolic pathway genes and risk of esophageal squamous cell carcinoma. Carcinogenesis (2013) 0.83
Reproductive factors and risk of oesophageal cancer, a population-based nested case-control study in Sweden. Br J Cancer (2012) 0.78
Predicting regression of Barrett's esophagus: results from a retrospective cohort of 1342 patients. Surg Endosc (2014) 0.76
Polymorphisms in Genes of Relevance for Oestrogen and Oxytocin Pathways and Risk of Barrett's Oesophagus and Oesophageal Adenocarcinoma: A Pooled Analysis from the BEACON Consortium. PLoS One (2015) 0.76
PIM1 polymorphism and PIM1 expression as predisposing factors of esophageal squamous cell carcinoma in the Asian population. Onco Targets Ther (2016) 0.75
Identification of estrogen responsive genes using esophageal squamous cell carcinoma (ESCC) as a model. BMC Syst Biol (2012) 0.75
Sex steroid hormones in relation to Barrett's esophagus: an analysis of the FINBAR Study. Andrology (2017) 0.75
Risk factors affecting the Barrett's metaplasia-dysplasia-neoplasia sequence. World J Gastrointest Endosc (2015) 0.75
Younger women have a better prognosis among patients with esophageal squamous cell carcinoma after esophagectomy. J Thorac Dis (2016) 0.75
Hormone factors play a favorable role in female head and neck cancer risk. Cancer Med (2017) 0.75
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials (1998) 20.39
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med (1999) 17.30
Esophageal cancer. N Engl J Med (2003) 15.23
The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst (2005) 8.90
Implementation of the Women's Health Initiative study design. Ann Epidemiol (2003) 7.30
Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst (2008) 6.00
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol (2007) 3.18
Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA (2003) 2.77
Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer (2002) 2.51
A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control (2001) 2.31
Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. Am J Epidemiol (2001) 2.30
A case-control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer (2000) 2.27
Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control (2000) 2.00
Socio-economic status and oesophageal cancer: results from a population-based case-control study in a high-risk area. Int J Epidemiol (2009) 1.77
Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol (2007) 1.62
Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst (2010) 1.60
Are racial differences in squamous cell esophageal cancer explained by alcohol and tobacco use? J Natl Cancer Inst (1994) 1.40
Do sex hormones play a role in the etiology of esophageal adenocarcinoma? A new hypothesis tested in a population-based cohort of prostate cancer patients. Cancer Epidemiol Biomarkers Prev (1998) 1.38
Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden. Br J Cancer (2006) 1.22
Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer (2006) 1.16
Socioeconomic factors and risk of esophageal adenocarcinoma: a nationwide Swedish case-control study. Cancer Epidemiol Biomarkers Prev (2005) 1.14
Sex hormones and oesophageal adenocarcinoma: influence of childbearing? Br J Cancer (2005) 1.08
The association of menstrual and reproductive factors with upper gastrointestinal tract cancers in the NIH-AARP cohort. Cancer (2010) 1.05
Oesophageal cancer in women: tobacco, alcohol, nutritional and hormonal factors. Br J Cancer (2001) 1.03
Radiation therapy for breast cancer and increased risk for esophageal carcinoma. Ann Intern Med (1998) 0.95
Significance of immunohistochemical expression of estrogen receptors alpha and beta in squamous cell carcinoma of the esophagus. Clin Cancer Res (2007) 0.95
Impact of radiotherapy in the risk of esophageal cancer as subsequent primary cancer after breast cancer. Int J Radiat Oncol Biol Phys (2006) 0.93
Estrogen and progesterone receptors in esophageal carcinoma. Dis Esophagus (2008) 0.89
Postmenopausal hormone therapy as a risk factor for gastroesophageal reflux symptoms among female twins. Gastroenterology (2008) 0.88
Patients with prostate cancer are less likely to develop oesophageal adenocarcinoma: could androgens have a role in the aetiology of oesophageal adenocarcinoma? Cancer Causes Control (2009) 0.87
Effects of estrogen with and without progestin and obesity on symptomatic gastroesophageal reflux. Gastroenterology (2008) 0.86
The risk of oesophageal cancer is not affected by a diagnosis of breast cancer. Eur J Cancer Prev (2010) 0.78
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Long-term exposure to air pollution and incidence of cardiovascular events in women. N Engl J Med (2007) 14.90
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol (2012) 5.70
Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst (2005) 5.52
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res (2007) 3.97
Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst (2007) 3.93
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2008) 3.73
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology (2003) 3.58
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA (2006) 3.29
Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer (2010) 3.27
Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control (2002) 3.27
Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol (2007) 3.18
Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst (2003) 3.07
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol (2008) 3.05
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97
Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst (2011) 2.84
Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women's Health Initiative. J Womens Health (Larchmt) (2013) 2.81
Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol (2008) 2.79
Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA (2011) 2.70
Frequency and predictive value of a mammographic recommendation for short-interval follow-up. J Natl Cancer Inst (2003) 2.64
The Women's Health Initiative Dietary Modification trial: overview and baseline characteristics of participants. Ann Epidemiol (2003) 2.64
Multivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative cohorts. Arch Intern Med (2009) 2.54
Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res (2003) 2.49
Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst (2013) 2.45
Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst (2014) 2.40
Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev (2007) 2.39
Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst (2007) 2.37
Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst (2007) 2.36
Selecting differentially expressed genes from microarray experiments. Biometrics (2003) 2.34
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol (2014) 2.25
Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res (2008) 2.24
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med (2007) 2.23
Central adiposity and risk of Barrett's esophagus. Gastroenterology (2007) 2.20
Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst (2005) 2.16
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Carbonated soft drink consumption and risk of esophageal adenocarcinoma. J Natl Cancer Inst (2006) 2.08
Racial disparities among patients with lung cancer who were recommended operative therapy. Arch Surg (2009) 2.02
Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer (2007) 2.01
Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol (2011) 2.00
A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology (2006) 1.98
Estimating kinship in admixed populations. Am J Hum Genet (2012) 1.95
A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) (2010) 1.89
Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann Intern Med (2014) 1.87
Influence of stressors on breast cancer incidence in the Women's Health Initiative. Health Psychol (2009) 1.75
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Statistical issues arising in the Women's Health Initiative. Biometrics (2005) 1.72
Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst (2008) 1.72
Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst (2006) 1.70
Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg (2010) 1.68
Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.67
A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet (2013) 1.67
Efficacy of exercise for menopausal symptoms: a randomized controlled trial. Menopause (2014) 1.67
American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol (2003) 1.64
Sex hormone levels and risk of breast cancer with estrogen plus progestin. J Natl Cancer Inst (2013) 1.60
Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst (2010) 1.60
Genetic variants in the MRPS30 region and postmenopausal breast cancer risk. Genome Med (2011) 1.55
Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study. J Natl Cancer Inst (2010) 1.55
Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol (2006) 1.54
Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res (2006) 1.52
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med (2003) 1.51
Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. J Natl Cancer Inst (2011) 1.51
Occupational exposures and risks of liver cancer among Shanghai female textile workers--a case-cohort study. Int J Epidemiol (2005) 1.50
The women's health initiative: lessons learned. Annu Rev Public Health (2008) 1.50
Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. J Clin Oncol (2012) 1.48